Prospective Sinonasal Cancer Multi-institution Study
ConditionSinonasal Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-99
SponsorMayo Clinic
About this trial
This is a multi-institution prospective study of patients with sinonasal malignancies. The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life. In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)
Patients with a diagnosis of sinonasal cancer
Patients undergoing treatment at Mayo Clinic
Disqualifiers
Healthy individuals
Unwilling to sign the informed consent
Trial population
Patients undergoing treatment for sinonasal cancers
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival
Time frame
Through study completion, an average of 5 yearsSecondary outcomes
1
Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)
Time frame
Through study completion, an average of 5 years2
Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles
Time frame
Through study completion, an average of 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov